Conditions: Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer
Keywords: non small cell lung cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 81
Healthy volunteers: no

Brief summary:
The primary objective of this study is to determine the major objective response rate of OSI-774 in participants with unresectable or metastatic bronchioloalveolar cell variant of non-small cell lung cancer.

This study is a Phase II study. The first study of OSI-774 was done to evaluate what dose should be given to patients with cancer has been completed. The purpose of this research study is to see whether this experimental treatment, called OSI-774, can cause a type of non-small cell lung cancer to stop growing or shrink. This study is sponsored by a company called Genentech, and is being done at Memorial Hospital, as well as other cancer centers around the country interested in developing new drugs for the treatment of this type of cancer.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: OSI-774: erlotinib, TarcevaTM
Intervention descriptions: intervention 1: 150 mg, 100 mg and 25 mg tablets

Protocol document: